TY - JOUR AU - de Melo Rodrigues, Ana Luiza AU - Lenzi, Luana AU - Lee-Jones, Lisa AU - Vieira Wanderley, Alayde AU - Marinho Da Silva, Ana Maria AU - Rocha De Carvalho, Cinthya AU - Teixeira Costa, Juliana AU - Galvão De Castro Junior, Cláudio AU - De Martino Lee, Maria Lucia AU - Mendes Lins, Mecneide AU - Rezende Godinho, Patrick AU - Correa Ribeiro, Raul PY - 2020/10/14 Y2 - 2024/03/29 TI - Leucemia mielóide aguda em crianças e adolescentes em instituições Brasileiras: realidade e desafios JF - JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY JA - jbmtct VL - 1 IS - 3 SE - Original article DO - 10.46765/2675-374X.2020v2n1p77-86 UR - https://www.jbmtct.com.br/seer/index.php/jbmtct/article/view/34 SP - 77-86 AB - <p>Objective: To describe the outcome of acute myeloid leukemia (AML) among children treated in Brazilian institutions. Methods: A structured online questionnaire was sent to pediatric oncologists affiliated to the Brazilian Society of Pediatric Oncology. The physicians and institutions were unidentified. Results: One hundred and four pediatric oncologists in all Brazilian regions answered the questionnaire. The treatment-related mortality rate was reported to be higher than 30% by 29.8% of the participants. Difficulty in accessing the intensive care unit (ICU) was reported by 54.8%. About 85% had access to cytogenetics, 78% to molecular testing, 94% to the measurement of residual disease by flow cytometry. About 90% of participants reported access to HSCT, but 86% of them had difficulties in providing HSCT timely. About 95% of the respondents indicated the need to create a national treatment protocol, and 89.4% are willing to collaborate with a national study group. Conclusion: Our study demonstrated large gaps in the treatment of pediatric AML in Brazil. To improve outcome, a national protocol will have to consider the regional differences and adapt the management according to the local resources.</p> ER -